ADAPT-DES registry data for ACS patients shows risk of Stent Thrombosis

Data on the ADAPT-DES registry presented at the 23rd annual Transcatheter Cardiovascular Therapeutics scientific symposium shows patients with Acute Coronary Syndrome and/or Diabetes who show poor response to dual antiplatelet therapy as measured by platelet function testing are at greater risk of stent thrombosis after PCI with drug-eluting stents. The researchers found that absolute and relative levels of platelet inhibition in response to ADP antagonists as assessed by the VerifyNow P2Y12 test are powerful independent predictors of stent thrombosis within 30 days, with a significant proportion of events independently attributable to clopidogrel hyoporesponsivenes. It suggest that agents which more effectively inhibit ADP-induced platelet activation should reduce 30-day stent thrombosis when applied to large patient populations. The degree of platelet responsiveness to antiplatelet loading is useful to predict 30-day stent thrombosis in diabetic and non-diabetic patients, as well as those with ACS, but may have less clinical utility in patients with stable coronary artery disease.